In addition, commercially available antibodies to measure Myb protein levels by immunohistochemistry can be problematic (data not shown), which could contribute to some of the reported differences in the fraction of ACC samples that express Myb proteins. This evidence concerns the gene MYB and adrenal cortex carcinoma.